Prinomastat

Prinomastat is an inhibitor of matrix metalloproteinase-2 (MMP-2), MMP-3, MMP-9, MMP-13, and MMP-14 (IC50s = 0.05, 0.3, 0.26, 0.03, and 0.33 nM, respectively). It is selective for these MMPs over MMP-1 and MMP-7 (IC50s = 8.3 and 54 nM, respectively). Prinomastat (50 mg/kg) reduces tumor growth and inhibits the formation of lung metastases in a murine Lewis lung carcinoma model. It also reduces the incidence of kidney, but not brain, metastasis and tumor microvessel density in an NCI H460 lung cancer orthotopic mouse model when administered at a dose of 100 mg/kg. Prinomastat reduces bronchoalveolar lavage fluid (BALF) levels of TNF-alpha and pulmonary edema in a rat model of ventilator-induced lung injury.Formal Name: (3S)-N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide. CAS Number: 192329-42-3. Synonyms: AG-3340, KB-R9896. Molecular Formula: C18H21N3O5S2. Formula Weight: 423.5. Purity: >95%. Formulation: (Request formulation change), A solid. Solubility: DMSO: Soluble. lambdamax: 229, 242 nm. SMILES: O=S(N1[C@H](C(C)(SCC1)C)C(NO)=O)(C2=CC=C(C=C2)OC3=CC=NC=C3)=O. InChi Code: InChI=1S/C18H21N3O5S2/c1-18(2)16(17(22)20-23)21(11-12-27-18)28(24,25)15-5-3-13(4-6-15)26-14-7-9-19-10-8-14/h3-10,16,23H,11-12H2,1-2H3,(H,20,22)/t16-/m0/s1. InChi Key: YKPYIPVDTNNYCN-INIZCTEOSA-N.